Journey Medical Corporation
DERM Healthcare Drug Manufacturers Specialty & Generic
Journey Medical Corporation’s revenue for fiscal 2025 (year ended December 2025) was $61.9 million, up 10.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.3%, EPS grew 93.8%, free cash flow fell 84.1% and total debt rose 1.43%, each against the same quarter a year earlier.
Follow DERM
Journey Medical Corporation (DERM) EV/Sales
As of 16 October 2026, Journey Medical Corporation (DERM) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from −0.1× (March 2022) to 3.9× (November 2025); the current reading is higher than 64% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.2× | 102.82% |
| FY2024 | 1.6× | 38.34% |
| FY2023 | 1.1× | 260.68% |
| FY2022 | 0.3× | 93.92% |
| FY2021 | 0.2× | (89.97%) |
| FY2020 | 1.6× | 0.00% |
| FY2019 | 1.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.9× | 46.18% |
| Mar 2026 | 2.0× | (38.32%) |
| Dec 2025 | 3.2× | 5.62% |
| Sep 2025 | 3.0× | (1.82%) |
| 21 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CLVR Clever Leaves Holdings Inc. compare | −0.3× |
| BGM BGM Group Ltd. compare | −0.1× |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| ORGO Organogenesis compare | 0.2× |
| AKBA Akebia Therapeutics, Inc. compare | 0.3× |
| OGI Organigram Global Inc. compare | 0.6× |
| PROCF Sofgen Pharma S.A compare | 0.7× |
| DERM Journey Medical Corporation | 2.0× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 2.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)